My research focuses on elucidating the molecular mechanisms underlying tumor progression, therapeutic resistance, and tumor-host interactions, with particular emphasis on aging, hypoxia, and the tumor immune microenvironment. By integrating multi-omics approaches, including transcriptomics, single-cell sequencing, proteomics, and clinical data analysis, I aim to identify key molecular determinants that drive treatment response and resistance in solid tumors, especially lung and breast cancers. A major area of interest in my work is the investigation of stress-adaptive mechanisms that enable tumor cells to survive radiotherapy and other anticancer treatments. I am particularly interested in regulated cell death pathways, including apoptosis, pyroptosis, ferroptosis, autophagy, and immunogenic cell death, and their roles in shaping anti-tumor immunity and therapeutic outcomes. My research also extends to pharmacology and translational oncology, focusing on the development and evaluation of novel therapeutic strategies, including molecularly targeted therapies, combination regimens, and nanomedicine-based drug delivery systems. Through interdisciplinary approaches bridging cancer biology, pharmacology, immunology, and clinical oncology, my long-term goal is to translate mechanistic discoveries into innovative therapeutic interventions that improve patient outcomes and advance precision cancer medicine.